Halozyme Therapeutics (HALO) Adds A New Director, Is It 21% Overvalued?

Halozyme Therapeutics board addition and recent financial signals

Halozyme Therapeutics (HALO) has drawn fresh attention after electing biotechnology executive Dannielle Appelhans to its Board of Directors, following a recent period of earnings disclosure, updated guidance, and share repurchases.

See our latest analysis for Halozyme Therapeutics.

Halozyme Therapeutics shares have shown strong momentum over 2026, with a 52.06% 90 day share price return, a 49.18% year to date share price return, and a 49.89% 1 year total shareholder return alongside higher reported revenue, earnings guidance and ongoing buybacks.

If this kind of move has you thinking about what else is out there, it could be a good moment to scan 42 healthcare AI stocks

Bulls point to Halozyme Therapeutics’ earnings guidance, buybacks and cash generation. Bears worry recent gains and board changes already reflect the good news. The valuation numbers help show which side the current evidence leans toward.

Most Popular Narrative: 20.7% Overvalued

The most followed valuation narrative puts Halozyme Therapeutics’ fair value at $86.89, which sits below the recent $104.89 close and frames the current optimism.

The analysts have a consensus price target of $86.89 for Halozyme Therapeutics based on their expectations of its future earnings growth, profit margins and other risk factors.

However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $96.0, and the most bearish reporting a price target of just $70.0.

Read the complete narrative.

Want to see what is sitting behind that valuation gap? The narrative hinges on steady revenue expansion, sharply higher margins and a materially different future earnings multiple.

Result: Fair Value of $86.89 (OVERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Halozyme Therapeutics still faces concentration risk around a few key partners and ongoing patent challenges that could unsettle revenue visibility if outcomes disappoint.

Find out about the key risks to this Halozyme Therapeutics narrative.

Another view on Halozyme Therapeutics valuation

Analyst targets suggest Halozyme Therapeutics is 20.7% above a fair value of $86.89, yet our SWS DCF model points in a very different direction. In this view, the DCF fair value is $405.09, which is far above the recent $104.89 share price. Which framework do you consider more useful for a long term view?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Halozyme Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 50 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

The mix of optimism and caution around Halozyme Therapeutics will mean different things for different investors, so move quickly and review the full picture for yourself. To weigh both sides in one place, start with the 2 key rewards and 3 important warning signs

Looking for more investment ideas beyond Halozyme Therapeutics?

If Halozyme Therapeutics has sharpened your focus, now is a smart time to widen your watchlist with other opportunities that could suit your style and risk comfort.

• Target resilient balance sheets by scanning companies in the solid balance sheet and fundamentals stocks screener (50 results) that pair financial strength with consistent fundamentals.
• Hunt for potential value opportunities by reviewing the 50 high quality undervalued stocks that highlight stocks with quality metrics and prices that may not fully reflect them yet.
• Spot possible future standouts early by checking the screener containing 20 high quality undiscovered gems that surface quality businesses receiving relatively limited market attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com